J&J chooses Yale to review requests for clinical drug data

(Reuters) – Johnson & Johnson has selected the Yale School of Medicine to review requests from investigators and physicians looking for access to clinical trial data involving the diversified healthcare company’s pharmaceuticals. Under the agreement, the “Yale Open Data Access Project,” will independently review and make final decisions regarding all requests for information on the company’s drug clinical trials, including anonymous patient data. The action comes amid growing pressure from outside scientists for access to raw data from clinical trials, reflecting general concerns that too many studies cannot be independently confirmed and may well be wrong. Britain’s GlaxoSmithkline Plc has set up an online system to provide researchers with access to anonymous patient-level data about its medicines.